SCHEMBL4702189

SCHEMBL4702189

COCCOc1ccc(CCNC(=O)/C=C/c2ccccn2)cc1S(N)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
MAPT P10636 5/20 0.47
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
PKM P14618 1/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
F10 P00742 1/20 0.43
ALOX5 P09917 1/20 0.43
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702198 1.00 KMT2A (0.48) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4701732 0.91 KMT2A (0.55) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4701739 0.91 KMT2A (0.55) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL7659576 0.88 MAPT (0.62) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL7659572 0.88 MAPT (0.62) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4704341 0.86 ABCC9 (0.51) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4704346 0.86 ABCC9 (0.51) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4704342 0.85 KMT2A (0.43) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4268259 0.84 KMT2A (0.42) KMT2AMAPTKDM4EALDH1A1PKM
SCHEMBL4705033 0.84 KMT2A (0.42) KMT2AMAPTKDM4EALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335902-B1 HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2008-10-08 EP disclosed
EP-1335902-A1 HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2003-08-20 EP disclosed
US-6472413-B2 FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-10-29 US disclosed
US-20020123495-A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-09-05 US disclosed
WO-2002036565-A1 HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123495-A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them KCNJ11, HCN3, CACNA1E KMT2A 2851/4885MAPT 4881/4885KDM4E 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.